Vertex Pharmaceuticals (VRTX) Short-term Investments (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Short-term Investments of $1.8 billion for Q1 2026, up 14.89% year-over-year from $1.5 billion in Q1 2025, and up 15.13% quarter-over-quarter from $1.5 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Short-term Investments (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- In Q1 2026, Short-term Investments rose 14.89% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 14.89% YoY), while the FY2025 annual figure was $1.5 billion, down 1.49% from the prior year.
- Short-term Investments for Q1 2026 stood at $1.8 billion, up from $1.5 billion in the prior quarter.
- The five-year high for Short-term Investments was $1.8 billion in Q1 2026, with the low at $274.5 million in Q4 2022.
- The 5-year median for Short-term Investments is $1.1 billion (2023), against an average of $1.1 billion.
- The sharpest annual moves came in 2022 and 2023: Short-term Investments tumbled 62.39% in 2022, then surged 209.36% in 2023.
- Vertex Pharmaceuticals' Short-term Investments stood at $274.5 million in 2022, then soared by 209.36% to $849.2 million in 2023, then jumped by 82.09% to $1.5 billion in 2024, then retreated by 1.49% to $1.5 billion in 2025, then gained by 15.13% to $1.8 billion in 2026.
- Business Quant data shows VRTX's Short-term Investments at $1.8 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Bn |
| Mar 31, 2026 | 1.75 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 1.41 Bn |
| Mar 31, 2025 | 1.53 Bn |
| Dec 31, 2024 | 1.55 Bn |
| Sep 30, 2024 | 1.29 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | 1.01 Bn |
| Dec 31, 2023 | 849.20 Mn |
| Sep 30, 2023 | 818.00 Mn |
| Jun 30, 2023 | 1.09 Bn |
| Mar 31, 2023 | 1.12 Bn |
| Dec 31, 2022 | 274.50 Mn |
| Sep 30, 2022 | 599.20 Mn |
| Jun 30, 2022 | 551.20 Mn |
| Mar 31, 2022 | 638.00 Mn |
| Dec 31, 2021 | 729.90 Mn |
| Sep 30, 2021 | 685.19 Mn |